This is a contract modification for a settlement termination at no cost. It incorporates a standard FAR clause prohibiting a specific application. The contract includes invoked option years covering performance from April 5, 2022, through April 4, 2024. The original solicitation was for Fenofibrate Nanocrystalize Tablets.